EPHA2 and cancer: Contrastingly, Cui et al. reported that deletion of any constituent enhancer within SEs downregulated EphA2 in multiple cancer cell lines (HeLa/HCT-116/MCF-7) [53], potentially attributable to conserved chromatin architecture.